PODD · Insulet Corp
$143.34
-3.10 (-2.12%)
At close · Aug 14
Market Cap
$9.94B
Shares
69.35M
Insulet Corp Earnings Call Transcripts
Every quarterly earnings call for Insulet Corp (PODD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲23.7%
$340.80M
−$5.20M
'22 Q3
22-11-03
▲20.1%
$369.70M
$17.00M
'22 Q4
23-02-23
▲21.2%
$358.10M
$23.80M
'23 Q1
23-05-04
▲32.4%
$396.50M
$27.30M
'23 Q2
23-08-08
▲27%
$432.70M
$51.90M
'23 Q3
23-11-02
▲37.9%
$509.80M
$103.30M
'23 Q4
24-02-22
▲23.3%
$441.70M
$51.50M
'24 Q1
24-05-09
▲23.2%
$488.50M
$188.60M
'24 Q2
24-08-08
▲25.7%
$543.90M
$77.50M
'24 Q3
24-11-07
▲17.2%
$597.50M
$100.70M
'24 Q4
25-02-20
▲28.8%
$569.00M
$35.40M
'25 Q1
25-05-08
▲32.9%
$649.10M
$22.50M
'25 Q2
25-08-07
▲29.9%
$706.30M
$87.60M
'25 Q3
25-11-06
▲31.2%
$783.70M
$101.60M
'25 Q4
26-02-18
▲33.9%
$761.70M
$91.10M
'26 Q1
26-05-06
LATEST
▲23.5%
$801.70M
$95.00M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Q2 2026 Insulet Corporation Earnings Call
Positive tone
Type 2 diabetes customer dynamics
Omnipod 5 commercial performance
2026 financial outlook
Revenue
$801.70M
▲ 23.5% YoY Diluted EPS
$1.37
▲ 328.1% YoY Gross margin
70.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
William Blair 46th Annual Growth Stock Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Insulet Corp Q1 FY2026 Earnings Call
Confident tone
U.S. Market Performance and Seasonality
Revenue Growth and Guidance Raise
Type 2 Diabetes Expansion
Revenue
$761.70M
▲ 33.9% YoY Diluted EPS
$1.30
▲ 160% YoY Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-18
Insulet Corp Q4 FY2025 Earnings Call
Confident tone
U.S. type 1 market leadership
U.S. type 2 expansion opportunity
Competitive moats and commercial capabilities
Revenue
$783.70M*
▲ 31.2% YoY Gross margin
72.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Insulet Corp Q3 FY2025 Earnings Call
Confident tone
Type 2 Expansion
U.S. Type 1 Market Leadership
International Growth
Revenue
$706.30M
▲ 29.9% YoY Diluted EPS
$1.24
▲ 14.8% YoY Gross margin
72.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Insulet Corp Q2 FY2025 Earnings Call
Confident tone
U.S. Type 2 market expansion
Omnipod 5 clinical differentiation and prescriber base
International growth and Omnipod 5 conversion
Revenue
$649.10M
▲ 32.9% YoY Diluted EPS
$0.32
▼ 87.6% YoY Gross margin
69.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Insulet Corp Q1 FY2025 Earnings Call
Confident tone
Omnipod 5 and innovation pipeline
New CEO leadership transition
U.S. type 2 expansion
Revenue
$569.00M
▲ 28.8% YoY Diluted EPS
$0.50
▼ 31.5% YoY Gross margin
71.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Insulet Corp Q4 FY2024 Earnings Call
Confident tone
Omnipod 5 adoption and customer milestones
Gross margin and manufacturing
Omnipod Discover launch
Revenue
$597.50M*
▲ 17.2% YoY Gross margin
72.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Insulet Corp Q3 FY2024 Earnings Call
Confident tone
Omnipod 5 Platform and Innovation
New Customer Starts
International Expansion
Revenue
$543.90M
▲ 25.7% YoY Diluted EPS
$1.08
▲ 45.9% YoY Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Insulet Corp Q2 FY2024 Earnings Call
Confident tone
Omnipod 5 growth and momentum
International expansion
Type 2 diabetes opportunity
Revenue
$488.50M
▲ 23.2% YoY Diluted EPS
$2.59
▲ 564.1% YoY Gross margin
67.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Insulet Corp Q1 FY2024 Earnings Call
Confident tone
International expansion (U.K., Germany, France, Netherlands)
GLP-1 impact on insulin adoption
Sensor integrations (Dexcom G7, Abbott Libre 2 Plus)
Revenue
$441.70M
▲ 23.3% YoY Diluted EPS
$0.73
▲ 114.7% YoY Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Insulet Corp Q4 FY2023 Earnings Call
Confident tone
Omnipod 5 growth and market leadership
Type 2 diabetes opportunity
Financial results and margin expansion
Revenue
$509.80M*
▲ 37.9% YoY Gross margin
70.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Insulet Corp Q3 FY2023 Earnings Call
Revenue
$432.70M
▲ 27% YoY Diluted EPS
$0.74
Gross margin
67.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Insulet Corp Q2 FY2023 Earnings Call
Revenue
$396.50M
▲ 32.4% YoY Diluted EPS
$0.39
Gross margin
66.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Insulet Corp Q1 FY2023 Earnings Call
Revenue
$358.10M
▲ 21.2% YoY Diluted EPS
$0.34
▼ 15% YoY Gross margin
67.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Insulet Corp Q4 FY2022 Earnings Call
Revenue
$369.70M*
▲ 20.1% YoY Gross margin
58.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Insulet Corp Q3 FY2022 Earnings Call
Revenue
$340.80M
▲ 23.7% YoY Diluted EPS
$-0.08
▼ 144.4% YoY Gross margin
55.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Insulet Corp Q2 FY2022 Earnings Call
Revenue
$299.40M
▲ 13.8% YoY Diluted EPS
$-0.50
Gross margin
63.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Insulet Corp Q1 FY2022 Earnings Call
Revenue
$295.40M
▲ 17.1% YoY Diluted EPS
$0.40
Gross margin
71.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Insulet Corp Q4 FY2021 Earnings Call
Revenue
$307.70M*
▲ 25% YoY Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Insulet Corp Q3 FY2021 Earnings Call
Revenue
$275.60M
▲ 17.8% YoY Diluted EPS
$0.18
▲ 5.9% YoY Gross margin
68.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Insulet Corp Q2 FY2021 Earnings Call
Revenue
$263.20M
▲ 16.3% YoY Diluted EPS
$-0.37
▼ 268.2% YoY Gross margin
69.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Insulet Corp Q1 FY2021 Earnings Call
Revenue
$252.30M
▲ 27.4% YoY Diluted EPS
$0.00
Gross margin
66.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Insulet Corp Q4 FY2020 Earnings Call
Revenue
$246.10M*
▲ 17.5% YoY Gross margin
65.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Insulet Corp Q3 FY2020 Earnings Call
Revenue
$234.00M
▲ 21.8% YoY Diluted EPS
$0.17
▲ 1600% YoY Gross margin
64.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Insulet Corp Q2 FY2020 Earnings Call
Revenue
$226.30M
▲ 27.8% YoY Diluted EPS
$0.22
▲ 1000% YoY Gross margin
63.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Insulet Corp Q1 FY2020 Earnings Call
Revenue
$198.00M
▲ 24.1% YoY Diluted EPS
$-0.03
▼ 142.9% YoY Gross margin
64.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Insulet Corp Q4 FY2019 Earnings Call
Revenue
$209.40M
▲ 27% YoY Diluted EPS
$0.08
▼ 50% YoY Gross margin
64.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1145197
CUSIP
45784P101
13F (30d)
683 filings
650 filers
Visit website
Investor relations